BPC-157 for SI joint and nerve pain: what the evidence actually shows

What did @peptidepaton actually say?

The creator describes a decade of back pain stemming from SI joint dysfunction and a "squint pelvis" that causes referred hamstring pain. They've been combining BPC-157 and TB-500 in the same vial (a combination sometimes called the "Wolverine Stack") and are now planning to add GHK-Cu and KPV to address inflammation and nerve pain. Critically, they're explicit that the peptides "are not a complete miracle" and that physio, glute training, core work, and mobility are still essential. That caveat matters. They're not claiming these compounds will fix their spine on their own.

The plan is structured: two months on a revised peptide protocol, running alongside a physical rehabilitation program. They list the compounds as anti-inflammatories aimed at inflammation, nerve pain, and recovery. No dosing instructions were given in this video, and no treatment timeline was promised.

Does the science back this up?

Partially, and with significant caveats. Most of the supporting data is preclinical, meaning rats and cell cultures, not humans with chronic SI joint dysfunction. That gap is real and should not be glossed over.

BPC-157 has the strongest preclinical profile of the compounds mentioned. Animal studies have shown it accelerates tendon-to-bone healing, reduces inflammatory markers, and appears to have some effect on nerve repair. Sikiric et al. (2018, Current Pharmaceutical Design) documented BPC-157's influence on nitric oxide pathways and nerve healing in rat models. TB-500 (a synthetic fragment of thymosin beta-4) has shown promise in cardiac and wound repair research, with Goldstein et al. (2012, Annals of the New York Academy of Sciences) noting its role in actin regulation and tissue repair signaling.

GHK-Cu, a copper peptide, has genuine anti-inflammatory and wound-healing literature behind it, largely in skin and soft tissue contexts. KPV is a tripeptide fragment of alpha-MSH with anti-inflammatory action in gut and skin research. Neither has been studied in SI joint or sciatic nerve contexts specifically. Calling all four compounds "anti-inflammatories" for nerve pain is a stretch from the current evidence base.

What did they get wrong, or right?

Credit where it's due: framing peptides as a complement to physio rather than a replacement is the right instinct. The creator is not telling people to skip their doctor and inject BPC-157 instead of getting an MRI. That responsible framing is genuinely unusual in this corner of TikTok.

What's oversimplified: describing GHK-Cu and KPV as anti-inflammatories that "help with nerve pain" for SI joint dysfunction specifically is not supported by human clinical data. There are no randomized controlled trials in this population for any of these compounds. The creator should not expect these peptides to act on chronic structural pain, which often involves nerve sensitization and joint laxity, in the same way they might support acute soft tissue injury recovery.

Combining BPC-157 and TB-500 in the same vial also raises stability and compatibility concerns that are not addressed. These are not trivially equivalent to taking them separately, and the research on combined preparations is essentially nonexistent.

What should you actually know?

SI joint dysfunction is notoriously difficult to treat. A 2019 review by Simopoulos et al. (Pain Physician) found that even interventional procedures like radiofrequency ablation show inconsistent outcomes. The creator's instinct to lean on glute strengthening, core stability, and mobility work is actually well-supported in the physiotherapy literature, Vleeming et al. (2012, European Spine Journal) specifically identified gluteal and multifidus muscle dysfunction as central to SI joint instability.

The peptides may offer some anti-inflammatory support and potentially some peripheral nerve signaling effects based on animal data, but anyone watching this should understand that none of these compounds are FDA-approved for this use, human trials are sparse, and self-administering injectable peptides without medical supervision carries real risks including infection and unknown long-term effects. If you have chronic back pain with a structural component, a physio and a spine specialist should be leading your care, with any peptide use discussed transparently with a licensed provider.

Bottom line on this stack

The creator is not making reckless claims, which puts this video above average for peptide content. But the evidence for these specific compounds in SI joint and nerve pain is thin, largely animal-based, and does not support confident claims of inflammation and nerve pain reduction in chronic structural back pain. The rehab plan is sound. The peptide rationale is speculative.